The role of metabonomics at the interface between drug metabolism and safety assessment

Current Drug Metabolism

Volumn 11, Issue 8, 2010, Pages 686-692

  Waters, Nigel J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Bioactivation; Biomarkers; Covalent binding; Drug discovery; Metabolic profiling; Metabolomics; Pharmacokinetics; Toxicology

Indexed keywords

DICARBOXYLIC ACID; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROSIGLITAZONE;

ARTICLE; DRUG METABOLISM; DRUG SAFETY; DRUG TOXICITY; HUMAN; LIQUID CHROMATOGRAPHY; MACROMOLECULE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; RISK ASSESSMENT; SPECTROSCOPY;

ANIMALS; DRUG DESIGN; HUMANS; LEAST-SQUARES ANALYSIS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS; PHARMACEUTICAL PREPARATIONS; PRINCIPAL COMPONENT ANALYSIS; XENOBIOTICS;

EID: 79952346802     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010794233512     Document Type: Article

References (56)

1. Kola, I. The state of innovation in drug development. Clin. Pharmacol. Ther., 2008, 83, 227-230.
2. Kola, I.; Landis, J. Opinion: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug. Discov., 2004, 3, 711-716.
3. Lindgren, S.; Bass Alan, S.; Briscoe, R.; Bruse, K.; Friedrichs Gregory, S.; Kallman Mary, J.; Markgraf, C.; Patmore, L.; Pugsley Michael, K. Benchmarking safety pharmacology regulatory packages and best practice. J. Pharmacol. Toxicol. Methods, 2008, 58, 99-109.
4. Muster, W.; Breidenbach, A.; Fischer, H.; Kirchner, S.; Mueller, L.; Paehler, A. Computational toxicology in drug development. Drug Discov. Today, 2008, 13, 303-310.
5. McKim, J. M. Jr. Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb. Chem. High. Throughput Screen., 2010, 13, 188-206.
6. Liebler, D. C.; Guengerich, F. P. Elucidating mechanisms of druginduced toxicity. Nat. Rev. Drug Discov., 2005, 4, 410-420.
7. Park, B. K.; Pirmohamed, M.; Kitteringham, N. R. Role of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective. Chem. Res. Toxicol., 1998, 11, 969-988. (Pubitemid 28447286)
8. Roth, R. A.; Ganey, P. E. Intrinsic versus idiosyncratic druginduced hepatotoxicity-two villains or one? J. Pharmacol. Exp. Ther., 332, 692-697.
9. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.; Nakai, Y.; O'Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab., 2005, 6, 161-225. (Pubitemid 40753853)
10. Marchant, C. A.; Briggs, K. A.; Long, A. In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for Windows, Meteor, and Vitic. Toxicol. Mech. Methods, 2008, 18, 177-187. (Pubitemid 351414973)
11. Wen, B.; Fitch, W. L. Analytical strategies for the screening and evaluation of chemically reactive drug metabolites. Expert. Opin. Drug Metab. Toxicol., 2009, 5, 39-55.
12. Riley, R. J.; Grime, K.; Weaver, R. Time-dependent CYP inhibition. Expert. Opin. Drug Metab. Toxicol., 2007, 3, 51-66. (Pubitemid 47315418)
13. Baillie, T. A.; Cayen, M. N.; Fouda, H.; Gerson, R. J.; Green, J. D.; Grossman, S. J.; Klunk, L. J.; LeBlanc, B.; Perkins, D. G.; Shipley, L. A. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol., 2002, 182, 188-196.
14. Smith, D. A.; Obach, R. S. Metabolites and safety: what are the concerns, and how should we address them? Chem. Res. Toxicol., 2006, 19, 1570-1579. (Pubitemid 44975120)
15. Evans, D. C.; Watt, A. P.; Nicoll-Griffith, D. A.; Baillie, T. A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 2004, 17, 3-16. (Pubitemid 38134055)
16. Bauman, J. N.; Kelly, J. M.; Tripathy, S.; Zhao, S. X.; Lam, W. W.; Kalgutkar, A. S.; Obach, R. S. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? an analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol., 2009, 22, 332-340.
17. Obach, R. S.; Kalgutkar, A. S.; Soglia, J. R.; Zhao, S. X. Can in. vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? an analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol., 2008, 21, 1814-1822.
18. Usui, T.; Mise, M.; Hashizume, T.; Yabuki, M.; Komuro, S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos., 2009, 37, 2383-2392.
19. Nakayama, S.; Atsumi, R.; Takakusa, H.; Kobayashi, Y.; Kurihara, A.; Nagai, Y.; Nakai, D.; Okazaki, O. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos., 2009, 37, 1970-1977.
20. Antoine, D. J.; Williams, D. P.; Park, B. K. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin. Drug Metab. Toxicol., 2008, 4, 1415-1427.
21. Dykens, J. A.; Will, Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today, 2007, 12, 777-785. (Pubitemid 47362789)
22. Nicholson, J. K.; Lindon, J. C.; Holmes, E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 1999, 29, 1181-1189.
23. Waters, N. J.; Garrod, S.; Farrant, R. D.; Haselden, J. N.; Connor, S. C.; Connelly, J.; Lindon, J. C.; Holmes, E.; Nicholson, J. K. High-resolution magic angle spinning 1h nmr spectroscopy of intact liver and kidney: optimization of sample preparation procedures and biochemical stability of tissue during spectral acquisition. Anal. Biochem., 2000, 282, 16-23. (Pubitemid 30409419)
24. Humpfer, E.; Spraul, M.; Nicholls, A. W.; Nicholson, J. K.; Lindon, J. C. Direct observation of resolved intracellular and extracellular water signals in intact human red blood cells using 1H MAS NMR spectroscopy. Magn. Reson. Med., 1997, 38, 334-336. (Pubitemid 27328263)
25. Wilson, I. D.; Plumb, R.; Granger, J.; Major, H.; Williams, R.; Lenz, E. M. HPLC-MS-based methods for the study of metabonomics. J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 2005, 817, 67-76. (Pubitemid 40174790)
26. Wilson, I. D.; Nicholson, J. K.; Castro-Perez, J.; Granger, J. H.; Johnson, K. A.; Smith, B. W.; Plumb, R. S. High resolution "ultra performance" liquid chromatography coupled to oa-tof mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J. Proteome. Res., 2005, 4, 591-598. (Pubitemid 40548168)
27. Theodoridis, G.; Wilson, I. D. Hyphenated techniques for global metabolite profiling. J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 2008, 871, 141-142.
28. Coen, M.; Holmes, E.; Nicholson, J. K.; Lindon, J. C. The development of a metabonomic-based drug safety testing paradigm. Toxicogenomics, 2008, 309-343.
29. Robertson, D. G.; Reily, M. D.; Baker, J. D. Metabonomics in pharmaceutical discovery and development. J. Proteome Res., 2007, 6, 526-539. (Pubitemid 46340156)
30. Beger, R. D.; Sun, J.; Schnackenberg, L. K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol., 243, 154-166.
31. Lindon, J. C.; Keun, H. C.; Ebbels, T. M. D.; Pearce, J. M. T.; Holmes, E.; Nicholson, J. K. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics, 2005, 6, 691-699. (Pubitemid 41479414)
32. Lindon, J. C.; Nicholson, J. K.; Holmes, E.; Antti, H.; Bollard, M. E.; Keun, H.; Beckonert, O.; Ebbels, T. M.; Reily, M. D.; Robertson, D.; Stevens, G. J.; Luke, P.; Breau, A. P.; Cantor, G. H.; Bible, R. H.; Niederhauser, U.; Senn, H.; Schlotterbeck, G.; Sidelmann, U. G.; Laursen, S. M.; Tymiak, A.; Car, B. D.; Lehman-McKeeman, L.; Colet, J.-M.; Loukaci, A.; Thomas, C. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol., 2003, 187, 137-146. (Pubitemid 36349345)
33. McBurney, R. N.; Hines, W. M.; von Tungeln, L. S.; Schnackenberg, L. K.; Beger, R. D.; Moland, C. L.; Han, T.; Fuscoe, J. C.; Chang, C.-W.; Chen, J. J.; Su, Z.; Fan, X.-h.; Tong, W.; Booth, S. A.; Balasubramanian, R.; Courchesne, P. L.; Campbell, J. M.; Graber, A.; Guo, Y.; Juhasz, P. J.; Li, T. Y.; Lynch, M. D.; Morel, N. M.; Plasterer, T. N.; Takach, E. J.; Zeng, C.; Beland, F. A. The liver toxicity biomarker study: phase I design and preliminary results. Toxicol. Pathol., 2009, 37, 52-64.
34. Waters, N. J.; Waterfield, C. J.; Farrant, R. D.; Holmes, E.; Nicholson, J. K. Integrated metabonomic analysis of bromobenzeneinduced hepatotoxicity: novel induction of 5-oxoprolinosis. J. Proteome Res., 2006, 5, 1448-1459. (Pubitemid 43865813)
35. Coen, M.; Lenz, E. M.; Nicholson, J. K.; Wilson, I. D.; Pognan, F.; Lindon, J. C. An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem. Res. Toxicol., 2003, 16, 295-303. (Pubitemid 36373694)
36. Holmes, E.; Loo, R. L.; Cloarec, O.; Coen, M.; Tang, H.; Maibaum, E.; Bruce, S.; Chan, Q.; Elliott, P.; Stamler, J.; Wilson, I. D.; Lindon, J. C.; Nicholson, J. K. Detection of urinary drug metabolite (xenometabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy. Anal. Chem. (Washington, DC, U. S.), 2007, 79, 2629-2640. (Pubitemid 46595614)
37. Sun, J.; Schnackenberg, L. K.; Beger, R. D. Studies of acetaminophen and metabolites in urine and their correlations with toxicity using metabolomics. Drug. Metab. Lett., 2009, 3, 130-136.
38. Clayton, T. A.; Baker, D.; Lindon, J. C.; Everett, J. R.; Nicholson, J. K. Pharmacometabonomic identification of a significant hostmicrobiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. USA, 2009, 106, 14728-14733, S14728/14721-S14728/14713.
39. Winnike, J. H.; Li, Z.; Wright, F. A.; Macdonald, J. M.; O'Connell, T. M.; Watkins, P. B. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin. Pharmacol. Ther. (N. Y. NY. U. S.). 88, 45-51.
40. Patterson, A. D.; Slanar, O.; Krausz, K. W.; Li, F.; Hofer, C. C.; Perlik, F.; Gonzalez, F. J.; Idle, J. R. Human urinary metabolomic profile of PPARa induced fatty acid b-oxidation. J. Proteome Res., 2009, 8, 4293-4300.
41. Mortishire-Smith, R. J.; Skiles, G. L.; Lawrence, J. W.; Spence, S.; Nicholls, A. W.; Johnson, B. A.; Nicholson, J. K. Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem. Res. Toxicol., 2004, 17, 165-173. (Pubitemid 38252496)
42. Bohus, E.; Racz, A.; Noszal, B.; Coen, M.; Beckonert, O.; Keun, H. C.; Ebbels, T. M. D.; Cantor, G. H.; Wijsman, J. A.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Metabonomic investigations into the global biochemical sequelae of exposure to the pancreatic toxin 1-cyano-2-hydroxy-3-butene in the rat. Magn. Reson. Chem., 2009, 47, S26-S35.
43. Patterson, A. D.; Gonzalez, F. J.; Idle, J. R. Xenobiotic metabolism: a view through the metabolometer. Chem. Res. Toxicol., 23, 851-860.
44. Sieber, M.; Hoffmann, D.; Adler, M.; Vaidya, V. S.; Clement, M.; Bonventre, J. V.; Zidek, N.; Rached, E.; Amberg, A.; Callanan, J. J.; Dekant, W.; Mally, A. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol. Sci., 2009, 109, 336-349.
45. Boudonck, K. J.; Rose, D. J.; Karoly, E. D.; Lee, D. P.; Lawton, K. A.; Lapinskas, P. J. Metabolomics for early detection of druginduced kidney injury: review of the current status. Bioanalysis, 2009, 1, 1645-1663.
46. Espina, J. R.; Shockcor, J. P.; Herron, W. J.; Car, B. D.; Contel, N. R.; Ciaccio, P. J.; Lindon, J. C.; Holmes, E.; Nicholson, J. K. Detection of in. vivo biomarkers of phospholipidosis using NMR-based metabonomic approaches. Magn. Reson. Chem., 2001, 39, 559-565.
47. Nicholls, A. W.; Nicholson, J. K.; Haselden, J. N.; Waterfield, C. J. A metabonomic approach to the investigation of drug-induced phospholipidosis: an NMR spectroscopy and pattern recognition study. Biomarkers, 2000, 5, 410-423. (Pubitemid 32016380)
48. Connor, S. C.; Hughes, M. G.; Moore, G.; Lister, C. A.; Smith, S. A. Antidiabetic efficacy of BRL 49653, a potent orally active insulin-sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by noninvasive [1H]NMR studies of urine. J. Pharm. Pharmacol., 1997, 49, 336-344. (Pubitemid 27197026)
49. Slim, R. M.; Robertson, D. G.; Albassam, M.; Reily, M. D.; Robosky, L.; Dethloff, L. A. Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitorinduced vascular lesions in rats. Toxicol. Appl. Pharmacol., 2002, 183, 108-116. (Pubitemid 35286139)
50. Robertson, D. G.; Reily, M. D.; Albassam, M.; Dethloff, L. A. Metabonomic assessment of vasculitis in rats. Cardiovasc. Toxicol., 2001, 1, 7-19.
51. Kumar, B. S.; Lee, Y.-J.; Yi, H. J.; Chung, B. C.; Jung, B. H. Discovery of safety biomarkers for atorvastatin in rat urine using mass spectrometry based metabolomics combined with global and targeted approach. Anal. Chim. Acta, 2010, 661, 47-59.
52. Bu, Q.; Yan, G.; Deng, P.; Peng, F.; Lin, H.; Xu, Y.; Cao, Z.; Zhou, T.; Xue, A.; Wang, Y.; Cen, X.; Zhao, Y.-L. NMR-based metabonomic study of the sub-acute toxicity of titanium dioxide nanoparticles in rats after oral administration. Nanotechnology, 2010, 21, 125105/125101-125105/125112.
53. Goodpaster, A. M.; Romick-Rosendale, L. E.; Kennedy, M. A. Statistical significance analysis of nuclear magnetic resonancebased metabonomics data. Anal. Biochem., 2010, 401, 134-143.
54. Castle, A. L.; Fiehn, O.; Kaddurah-Daouk, R.; Lindon, J. C. Metabolomics Standards Workshop and the development of international standards for reporting metabolomics experimental results. Brief. Bioinf., 2006, 7, 159-165. (Pubitemid 44404882)
55. Griffin, J. L.; Steinbeck, C. So what have data standards ever done for us? The view from metabolomics. Genome Med., 2010, 2, 38.
56. Villas-Boas, S. G.; Koulman, A.; Lane, G. A. Analytical methods from the perspective of method standardization. Top. Curr. Genet., 2007, 18, 11-52.